Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

Jonathan A. Bernstein(University of Cincinnati Medical Center), Mark Weinstein, M. Dawn Goodyear, Douglas Johnston, Richard F. Lockey(University of South Florida), Alan P. Baptist(Henry Ford Health System), Maureen Watt(La Jolla Institute for Immunology), Hugo Chapdelaine, H. Henry Li, Aleena Banerji(Massachusetts General Hospital), Rafael Zaragoza-Urdaz(University of Puerto Rico System), Raffi Tachdjian(University of California, Los Angeles), Daniel Nova Estepan(Takeda (United States)), John Anderson, Stephen Betschel(University of Toronto), Paula J. Busse(Massachusetts General Hospital), Daniel Soteres(Vinmec International Hospital), Bruce L. Zuraw(Scripps Research Institute), Selina Gierer, Timothy Craig(Penn State Milton S. Hershey Medical Center), H. James Wedner(Washington University in St. Louis), Daniel Petroni(Allergy, Asthma and Clinical Research Center), Florence Ida Hsu, Jason Raasch, Patricia Lugar, Alexander Kim, Salomé Juethner(Takeda (United States)), William R. Lumry(American Association for Respiratory Care), Michael Manning(University of Puerto Rico System), Natalie Khutoryansky(Henry Ford Health System), Rémi Gagnon, Paul K. Keith, Jay M. Kashkin(Takeda (United States))
Advances in Therapy
June 12, 2025
Cited by 10


Related Papers